Bellusci, Lorenza
Grubbs, Gabrielle http://orcid.org/0000-0003-4302-9535
Zahra, Fatema Tuz
Forgacs, David
Golding, Hana
Ross, Ted M.
Khurana, Surender http://orcid.org/0000-0002-0593-7965
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (75N93019C00052)
University of Georgia (GRA-001)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002378)
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (intramural FDA-CBER COVID-19 supplemental funds, FDA’s MCMi grant #OCET 2021-1565)
U.S. Department of Health & Human Services | U.S. Food and Drug Administration
Article History
Received: 11 April 2022
Accepted: 25 July 2022
First Online: 8 August 2022
Competing interests
: The authors declare no competing interests.
: The study at CBER, FDA, was conducted with de-identified samples and all assays performed fell within the permissible usages in the original consent. Antibody assays were performed with approval from the U.S. Food and Drug Administration’s Research Involving Human Subjects Committee (FDA-RIHSC) under exemption protocol ‘252-Determination- CBER-2020-08-19.